Safety of tocilizumab in the treatment of juvenile idiopathic arthritis

Systemic-onset juvenile idiopathic arthritis

(2016) Rolando Cimaz   AUTOIMMUNITY REVIEWS

The biology behind interleukin-6 targeted interventions

(2016) Xiao Liu et al.   CURRENT OPINION IN RHEUMATOLOGY

Clinical outcome measures in juvenile idiopathic arthritis

(2016) Alessandro Consolaro et al.   Pediatric Rheumatology

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)

(2015) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan

(2015) Shumpei Yokota et al.   ANNALS OF THE RHEUMATIC DISEASES

Advances in the treatment of polyarticular juvenile idiopathic arthritis

(2015) Kate Webb et al.   CURRENT OPINION IN RHEUMATOLOGY

Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab

(2015) S. Yokota et al.   JOURNAL OF RHEUMATOLOGY

Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases

(2015) Daniella M. Schwartz et al.   Nature Reviews Rheumatology

Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials

(2015) Simon Tarp et al.   RHEUMATOLOGY

Biologic-Associated Infections in Pediatric Rheumatology

(2015) Gerd Horneff   Current Rheumatology Reports

Vaccinations in Paediatric Rheumatology: an Update on Current Developments

(2015) Noortje Groot et al.   Current Rheumatology Reports

Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial

(2014) Hermine I Brunner et al.   ANNALS OF THE RHEUMATIC DISEASES

Macrophage activation syndrome and cytokine-directed therapies

(2014) Grant S. Schulert et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Neutrophil CD64 as a marker of infection in patients treated with tocilizumab

(2014) Toshihiro Matsui et al.   Modern Rheumatology

Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis

(2014) Tomoyuki Imagawa et al.   Modern Rheumatology

Treatment of juvenile idiopathic arthritis: a revolution in care

(2014) Matthew L Stoll et al.   Pediatric Rheumatology

The Biology and Medical Implications of Interleukin-6

(2014) T. Tanaka et al.   Cancer Immunology Research

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

(2012) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

(2012) Fabrizio De Benedetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

EULAR recommendations for vaccination in paediatric patients with rheumatic diseases

(2011) M. W. Heijstek et al.   ANNALS OF THE RHEUMATIC DISEASES

Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis

(2011) Gregor Dueckers et al.   CLINICAL IMMUNOLOGY

Juvenile idiopathic arthritis

(2011) Berent Prakken et al.   LANCET

Clinical value of blocking IL-6 receptor

(2010) Toru Mima et al.   CURRENT OPINION IN RHEUMATOLOGY

Inflammatory cytokines and the GH/IGF-I axis: novel actions on bone growth

(2009) C. Pass et al.   CELL BIOCHEMISTRY AND FUNCTION

Neutrophil CD64: a diagnostic marker for infection and sepsis

(2009) Johannes J.M.L. Hoffmann   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Inflammatory cytokines in juvenile idiopathic arthritis: Effects on physical growth and the insulin-like-growth factor axis

(2008) S.C. Wong et al.   GROWTH HORMONE & IGF RESEARCH

Growth Velocity and Interleukin 6 Concentrations in Juvenile Idiopathic Arthritis

(2008) Leticia S. Souza et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

(2008) Shumpei Yokota et al.   LANCET